INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic "Family Beginnings"
MWN-AI** Summary
INVO Fertility, Inc. (Nasdaq: IVF) has successfully completed its acquisition of Family Beginnings, P.C., a well-respected fertility clinic located in Indiana. This strategic move, initially announced in December 2025, aligns with INVO's mission to enhance access to high-quality fertility care. Family Beginnings, established over a decade ago, is recognized for its comprehensive range of services, which include in vitro fertilization (IVF), ovulation induction, and fertility preservation, delivered with a patient-centered approach. The clinic's reputation is bolstered by Dr. James Donahue, a renowned reproductive endocrinologist who has been honored as a top doctor, reflecting his dedication to patient care.
The acquisition, valued at $760,000, enables INVO to bolster its operational capabilities while ensuring continuity for existing patients, as Dr. Donahue and his team will remain in place. This addition is expected to significantly impact INVO's overall revenue, as Family Beginnings generated approximately $1 million in revenue and $200,000 in net income for the nine months ending September 30, 2025, accounting for about 18% of INVO's clinic revenue during that period.
CEO Steve Shum expressed enthusiasm about the acquisition, underscoring its role in expanding INVO's footprint and enhancing their portfolio of fertility services. The integration of Family Beginnings is part of INVO’s broader strategy to grow through targeted acquisitions and organic initiatives, providing advanced reproductive technologies, including its proprietary INVOcell device, which promotes a more intimate and affordable patient experience.
This acquisition marks a significant milestone for INVO Fertility as it seeks to lead in expanding access to assisted reproductive technology (ART) across the Midwest and beyond.
MWN-AI** Analysis
The recent acquisition of Family Beginnings by INVO Fertility represents a significant strategic move for the company, expanding its geographic footprint and reinforcing its commitment to high-quality, personalized fertility care. This acquisition is aligned with broader industry trends favoring consolidation and the establishment of comprehensive networks in healthcare services.
From a financial perspective, INVO's successful acquisition of Family Beginnings, which generated approximately $1 million in revenue for the nine months ending September 30, 2025, provides an immediate boost to the company’s revenue base. The clinic’s operational model and strong patient-first reputation are anticipated to enhance INVO’s existing portfolio, potentially attracting more patients and increasing overall clinic performance.
However, investors should consider potential risks. The fertility market is highly competitive, and while INVO's business model focuses on the innovative INVOcell technology, the success of this acquisition will depend on the effective integration of Family Beginnings into INVO’s operations and the continued effectiveness of its marketing strategies to attract new patients.
Moreover, the commitment to maintain Family Beginnings' current medical leadership is a positive sign, as continuity in care and operational stability are essential to successfully retaining patient loyalty and trust. Dr. James Donahue’s continued leadership can facilitate this process, leveraging his established reputation to promote INVO's services effectively.
As you consider investing in INVO Fertility, weigh these factors against your investment strategy and risk tolerance. With its growth-focused approach and recent strategic moves, INVO may offer an exciting opportunity, particularly as demand for fertility services continues to rise. However, ongoing scrutiny of operational performance and market conditions will be key to understanding the company’s trajectory moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SARASOTA, Fla., Feb. 19, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it has successfully closed the previously announced acquisition of Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest.
The transaction was completed in accordance with the terms of the definitive purchase agreement first announced on December 17, 2025.
Founded more than a decade ago, Family Beginnings has built a strong reputation for delivering comprehensive fertility services with a highly personalized, patient-first approach. The clinic offers a full suite of reproductive services, including in vitro fertilization, intravaginal culture (as an early adopter of the Company’s INVOcell solution), ovulation induction, intrauterine insemination, fertility preservation, and diagnostic testing, supported by an experienced clinical and embryology team. James Donahue, M.D., Family Beginnings REI and lab director, was recognized again as a 2026 Castle Connolly Top Doctor, placing him among the top 7% of physicians in the U.S. and reflecting his many years of dedicated and quality service to patients.
Family Beginnings is known for its continuity of care, close physician-patient relationships, and commitment to guiding patients through what is often a complex and emotional journey. These attributes align closely with INVO Fertility’s mission to expand access to high-quality, compassionate fertility care while maintaining a personalized treatment experience.
Importantly for patients, the clinic’s existing medical leadership and care teams will remain in place, ensuring continuity of care while benefiting from INVO’s broader clinical resources, operational support, and ongoing investment in advanced technologies and best practices.
Family Beginnings generated revenue of approximately $1 million and net income of approximately $0.2 million for the 9 months ended September 30, 2025, or approximately 18% of INVO’s clinic revenue for the same period.
The closing of this acquisition marks an important milestone in INVO’s ongoing strategy to expand its network of fertility care centers and broaden patient access to advanced reproductive care. Under the terms of the transaction, INVO acquired the non-clinical assets of Family Beginnings for a combined purchase price of $760,000, comprised of cash and preferred stock consideration. James Donahue, M.D. will continue to lead the clinic’s operations under a multi-year agreement.
“We are thrilled to complete the acquisition of Family Beginnings,” said Steve Shum, CEO of INVO Fertility. “This transaction not only expands our geographic footprint and enhances our portfolio of clinics, but it also advances our mission of increasing access to high-quality, patient-centered fertility care. Family Beginnings has a long-standing reputation for excellence and compassionate care, and we look forward to building on that legacy with Dr. Donahue and growing the clinic from its current operating levels.”
The closing of the Family Beginnings acquisition follows a period of meaningful progress for INVO Fertility, as highlighted in the Company’s recent shareholder letter, which underscores the clear strategic outlook centered on growth through both organic initiatives and targeted clinic acquisitions, as well as the Company enjoying its strongest fundamental position in several years.
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination. For more information, please visit invofertility.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding the Company’s ability to satisfy closing conditions for the offering, our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
FAQ**
How does the acquisition of Family Beginnings enhance INVO Fertility Inc. IVF's competitive position in the fertility clinic market across the Midwest?
What specific strategies does INVO Fertility Inc. IVF plan to implement to integrate Family Beginnings into its existing operations and expand its patient base?
Given the promising revenue figures reported by Family Beginnings, how does INVO Fertility Inc. IVF anticipate improving profitability through this acquisition?
What are the long-term goals for INVO Fertility Inc. IVF in terms of technological advancements and clinical practices following the integration of Family Beginnings?
**MWN-AI FAQ is based on asking OpenAI questions about INVO Fertility Inc. (NASDAQ: IVF).
NASDAQ: IVF
IVF Trading
4.76% G/L:
$0.88 Last:
88,243 Volume:
$0.8275 Open:
